Encompass Health Corporation $EHC Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its stake in shares of Encompass Health Corporation (NYSE:EHC) by 6.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 464,049 shares of the company’s stock after selling 31,127 shares during the quarter. Victory Capital Management Inc. owned about 0.46% of Encompass Health worth $58,944,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Tectonic Advisors LLC boosted its position in Encompass Health by 1.6% during the third quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock worth $678,000 after purchasing an additional 82 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Encompass Health by 23.0% in the third quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock valued at $57,000 after buying an additional 84 shares in the last quarter. EP Wealth Advisors LLC raised its stake in shares of Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after buying an additional 88 shares during the last quarter. Natural Investments LLC boosted its position in shares of Encompass Health by 1.2% in the 3rd quarter. Natural Investments LLC now owns 7,808 shares of the company’s stock worth $991,000 after buying an additional 89 shares in the last quarter. Finally, TD Private Client Wealth LLC grew its stake in Encompass Health by 1.1% in the 3rd quarter. TD Private Client Wealth LLC now owns 8,216 shares of the company’s stock valued at $1,044,000 after acquiring an additional 91 shares during the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Stock Performance

EHC opened at $106.89 on Friday. Encompass Health Corporation has a twelve month low of $92.53 and a twelve month high of $127.99. The stock has a market cap of $10.63 billion, a PE ratio of 19.29, a price-to-earnings-growth ratio of 2.06 and a beta of 0.71. The business’s 50 day moving average is $103.93 and its 200-day moving average is $113.71. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.17. The company had revenue of $3.09 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.17 EPS. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. On average, analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be issued a dividend of $0.19 per share. The ex-dividend date is Wednesday, April 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is currently 13.72%.

Analysts Set New Price Targets

EHC has been the topic of several recent research reports. Zacks Research downgraded shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Barclays increased their price target on shares of Encompass Health from $150.00 to $153.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Finally, Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $143.29.

Insider Transactions at Encompass Health

In other news, CEO Mark J. Tarr sold 150,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the transaction, the chief executive officer owned 377,070 shares in the company, valued at approximately $42,096,094.80. The trade was a 28.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.